Investors are constantly on the lookout for catalysts that can influence price movements. One major driver that frequently affects stock prices is news, especially when it’s positive. Such news has the potential to propel stocks to new heights.
Let’s now introduce four stocks with recent positive news that have the potential to grab investors’ attention:
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a cutting-edge diagnostic and medical device technology company, announced a game-changing partnership on September 13, 2023. The company has joined forces with Hero LifeCare, a renowned healthcare and emergency device solutions provider based in the United States.
Hero LifeCare is celebrated for its innovative healthcare and emergency response products. One of its notable creations is the FDA-cleared R15, a first-aid emergency oxygen device developed in collaboration with the University of Michigan. Hero LifeCare’s extensive network and deep connections within the medical and healthcare industries make it a powerful partner for Therma Bright.
This strategic alliance aims to introduce and market Therma Bright’s Venowave device to a broader audience. With Hero LifeCare as its distribution partner, Therma Bright is poised to tap into new markets and amplify its presence in the United States. The partnership provides Therma Bright with access to a vast customer base and direct-to-consumer opportunities through Hero LifeCare’s e-commerce platform.
The significance of this partnership extends beyond immediate sales opportunities. It underscores Therma Bright’s dedication to advancing healthcare solutions. By bringing Venowave, a compact and lightweight Deep Vein Thrombosis (DVT) prevention device, to a wider audience, Therma Bright is contributing to the prevention of life-threatening blood clotting complications. With about 50% of DVTs beginning to form intra-operatively and 75% forming within 48 hours post-operatively, Venowave’s accessibility becomes increasingly critical.
Investors keen on healthcare technology stocks should keep a close eye on Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF). This partnership with Hero LifeCare has the potential to open up new revenue streams and establish Therma Bright as a prominent player in the healthcare industry. As the company continues to expand its distribution partnerships and secure FDA approvals, its stock may present an attractive addition to investors’ watchlists.
Therma Bright’s strategic partnership with Hero LifeCare marks a significant milestone in the company’s journey towards transforming healthcare. With innovative solutions like Venowave,TBRIF. could make a lasting impact on patient care and healthcare technology.
In a significant development for Northwest Biotherapeutics (OTCQB: NWBO), the biotechnology company specializing in personalized immune therapies for solid tumor cancers, Dr. Linda Liau, MD, PhD, MBA, has recently become a member of the Company’s Scientific Advisory Board (SAB). Dr. Liau brings with her a wealth of expertise and experience in the field of neuro-oncology, making her a valuable addition to the board.
Dr. Liau played a pivotal role as the Principal Investigator of the Phase 3 trial of DCVax-L, one of Northwest Biotherapeutics’ key programs aimed at treating glioblastoma, an aggressive and often fatal form of brain cancer. Her extensive background includes serving as the Chair of the Department of Neurosurgery at UCLA, where she also acts as the Director of the UCLA Brain Tumor Program. Dr. Liau’s contributions to the scientific community extend to her previous role as the Editor-in-Chief of the Journal of Neuro-Oncology and her membership in the National Academy of Medicine.
Northwest Biotherapeutics has a robust platform technology for DCVax dendritic cell-based vaccines, with DCVax-L as its lead program. DCVax-L has undergone a Phase 3 trial involving 331 patients with newly diagnosed glioblastoma. Glioblastoma is known for its aggressive nature and limited treatment options, making this trial of utmost importance. Notably, this Phase 3 trial has already been completed, with results presented at scientific meetings and published in JAMA Oncology.
Dr. Liau’s inclusion in the Scientific Advisory Board further strengthens Northwest Biotherapeutics’ position as it advances toward DCVax-L approval and explores future clinical programs rooted in its research and expertise. The Company’s existing distinguished SAB members, including Dr. Samir Khleif, Dr. Jerome Galon, Dr. John Smyth, and the late Dr. Mac Cheever, have laid the foundation for cutting-edge cancer research, and Dr. Liau’s contributions are expected to complement and enhance this ongoing work.
iQSTEL Inc. (OTC-QX: IQST), a dynamic telecommunications company based in the United States, is making significant strides towards its goal of uplisting on the Nasdaq Stock Market. As part of this strategic move, the company recently executed a term sheet with LDA Capital, securing $10 million in support for its Nasdaq uplisting plans.
iQSTEL Inc. has been on a remarkable growth trajectory, reporting revenues of $93.2 million last year. In 2023, the company projected revenues of $120 million. These impressive figures have garnered attention from investors and are indicative of the company’s potential for further growth and expansion.
LDA Capital, an alternative investment group with a track record of successful investments, has partnered with iQSTEL Inc. for this endeavor. The firm specializes in complex, cross-border transactions and has launched a $2 billion fund aimed at making regionally specific investments in high-growth companies, both publicly listed and pre-IPO.
The $10 million investment from LDA Capital is expected to occur in two tranches. The first $5 million will be placed in exchange for a 24-month bond, which will be used to expand iQSTEL’s core telecommunications business. This expansion may include the acquisition of disruptive innovations and businesses with positive financial fundamentals, including revenue and net income.
The second $5 million will be placed in exchange for a second $5 million bond following a successful uplisting to Nasdaq. iQSTEL Inc. is optimistic about the potential impact of this partnership with LDA Capital, believing it could elevate the company’s market visibility and market cap, aligning it more closely with its underlying value.
While the term sheet is not binding on the parties, the due diligence process and anticipated definitive investment agreement will pave the way for further developments in this exciting chapter for iQSTEL Inc.
Investors and industry observers will undoubtedly keep a keen eye on iQSTEL Inc. as it continues to navigate the path towards the Nasdaq and explores the potential for future growth and expansion in the telecommunications sector.
Talon Metals Corp. (TSX: TLO) (TLOFF) is poised to significantly enhance domestic nickel exploration efforts following a strategic agreement with the Department of Defense’sOffice of Manufacturing Capability Expansion and Investment Prioritization. This collaboration demonstrates the strategic importance of nickel for national security and clean energy systems, driven by a shared commitment to ensuring a stable supply of nickel for both the growing US battery manufacturing sector and defense-related supply chains.
In accordance with this agreement, Talon will contribute $21,783,150 on a cost-sharing basis, with Talon matching the Department of Defense’s substantial funding contribution of $20,607,146. This funding marks a pivotal step towards achieving American independence in the supply of critical minerals, reducing reliance on foreign sources, particularly Russia and China, for nickel, a vital component in defense platforms and clean energy systems.
Talon’s exploration efforts focus on the Midcontinent Rift geology of the United States, specifically the Lake Superior region of Minnesota and Michigan. The company’s comprehensive approach aligns with the US Geological Survey’s perspective on the region’s high prospectivity for nickel sulfide deposits, potentially leading to “district-scale” mineralization.
Henri van Rooyen, CEO of Talon, emphasized the responsibility that comes with this funding, highlighting the need to balance resource discovery with environmental conservation, job creation, community engagement, and tribal participation. Talon’s commitment to best-in-class exploration practices aims to safeguard the natural environment in the areas where it operates.
Talon’s exploration activities are currently focused on the Tamarack Intrusive Complex in central Minnesota, with recent successes in nickel exploration. Additionally, the company has acquired mineral rights in the Upper Peninsula of Michigan, strategically located near the only operational nickel mine in the US. With a fleet of five drill rigs and an in-house team of geophysicists, Talon is well-positioned to leverage the Department of Defense’s funding to expand and accelerate exploration efforts in Minnesota and Michigan.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance that are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Therma Bright to assist in the production and distribution of content related to TBRIF. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.